Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 20;8(1):17131.
doi: 10.1038/s41598-018-35457-6.

Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers

Affiliations

Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers

Etsuko Tokunaga et al. Sci Rep. .

Abstract

Twenty years after the thalidomide disaster in the late 1950s, Blaschke et al. reported that only the (S)-enantiomer of thalidomide is teratogenic. However, other work has shown that the enantiomers of thalidomide interconvert in vivo, which begs the question: why is teratogen activity not observed in animal experiments that use (R)-thalidomide given the ready in vivo racemization ("thalidomide paradox")? Herein, we disclose a hypothesis to explain this "thalidomide paradox" through the in-vivo self-disproportionation of enantiomers. Upon stirring a 20% ee solution of thalidomide in a given solvent, significant enantiomeric enrichment of up to 98% ee was observed reproducibly in solution. We hypothesize that a fraction of thalidomide enantiomers epimerizes in vivo, followed by precipitation of racemic thalidomide in (R/S)-heterodimeric form. Thus, racemic thalidomide is most likely removed from biological processes upon racemic precipitation in (R/S)-heterodimeric form. On the other hand, enantiomerically pure thalidomide remains in solution, affording the observed biological experimental results: the (S)-enantiomer is teratogenic, while the (R)-enantiomer is not.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
(S)- and (R)-enantiomers of thalidomide (1).
Figure 2
Figure 2
Self-disproportionation of non-racemic 1 (for Table 1).
Figure 3
Figure 3
Self-disproportionation of non-racemic 1 in water and phosphate buffer (pH = 7) (for Table 2).
Figure 4
Figure 4
Self-disproportionation of non-racemic thalidomide at practical scale; aDMSO (0.25 mL) was used.
Figure 5
Figure 5
Structures of the (S/S)-homodimer and the (R/S)-heterodimer of 1 based on X-ray crystallographic analyses.
Figure 6
Figure 6
(a) Mechanism of the SDE for (R)-1. (b) An SDE-based hypothesis that feasibly explains why (R)-1 does not show any teratogenic effect in vivo.
Figure 7
Figure 7
Self-disproportionation of non-racemic 2 in water. (S)-2 (23% ee, 5 mg) was dissolved in DMSO, and the SDE experiment was carried out upon addition of water. The final ee was determined from the supernatant after 1 h of stirring by HPLC using a CHIRALCEL OJ-H column with ethanol as the eluent. A substantial amount of precipitate was also observed.

References

    1. Burley DM, Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962;279:271–272. doi: 10.1016/S0140-6736(62)91217-5. - DOI
    1. Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203–215. doi: 10.1002/tera.1420380303. - DOI - PubMed
    1. Diggle GE. Thalidomide: 40 years on. Int J Clin Pract. 2001;55:627–631. - PubMed
    1. Stephens TD. Proposed mechanisms of action in thalidomide embryopathy. Teratology. 1988;38:229–239. doi: 10.1002/tera.1420380307. - DOI - PubMed
    1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer. 2004;4:314. doi: 10.1038/nrc1323. - DOI - PubMed

Publication types